Side effects among healthcare workers from a large Milan university hospital after second dose of BNT162b2 mRNA COVID-19 vaccine

Main Article Content

Elisa Borroni
Dario Consonni
Massimo Cugno
Andrea Lombardi
Davide Mangioni
Patrizia Bono
Massimo Oggioni
Sara Uceda Renteria
Lorenzo Bordini
Carlo Domenico Nava
Matteo Letzgus
Flaminia Gentiloni Silverj
Silvana Castaldi
Magda Rognoni
Luca Cavallieri D'Oro
Michele Carugno
Luciano Riboldi
Ferruccio Ceriotti
Alessandra Bandera
Andrea Gori
Angela Cecilia Pesatori

Keywords

COVID-19 Vaccination, Healthcare Workers, Adverse Events

Abstract

Background: In Italy, healthcare workers (HCWs) were among the first to receive COVID-19 vaccination. Aim of the present study is to evaluate frequency and severity of adverse events (AEs) following the second dose of BNT162b2 vaccine among HCWs of a large university hospital in Milan, Italy. Methods: One month after having received the second dose of vaccine, HCWs filled-in a form about type, severity, and duration of post-vaccination local and systemic symptoms. We calculated the overall frequency of AEs and used multivariable Poisson regression models (adjusted for sex, age, BMI, smoking, allergy history, previous SARS-CoV-2 infection, anti-hypertensive therapy, and occupation) to calculate risk ratios (RR) and 95% confidence intervals (CI) of AEs according to selected variables. Results: We included 3659 HCWs. Overall, 2801 (76.6%) experienced at least one local event, with pain at injection site being the most frequent (2788, 76.2%). Systemic events were reported by 2080 (56.8%) HCWs, with fatigue (52.3%), muscle pain (42.2%), headache (37.7%), joint pain (31.9%), and fever (26.2%) being the most frequent. Risks of systemic events were associated with female gender (RR=1.14, CI: 1.06-1.23), age (strong decrease with increasing age, p-trend<0.001), allergy history (RR=1.13, CI: 1.05-1.20), and current smoking (RR=0.90, CI: 0.84-0.97). HCWs with previous SARS-CoV-2 infection (even if symptomatic) were not at increased risk. Conclusions: Both local and systemic acute effects after second dose of BNT162b2 vaccine were frequently reported. However, symptoms were mostly light/mild and of short duration. Thus, our findings support the safety of COVID-19 vaccination in adults in relatively good health.

Downloads

Download data is not yet available.
Abstract 235 | PDF Downloads 177 Supplementary files Downloads 39

References

1. Johns Hopkins University and Medicine. Coronavirus Resource Center. Published 2021. Accessed October 14, 2021. https://coronavirus.jhu.edu/
2. Haque A, Pant AB. Efforts at COVID-19 Vaccine Development: Challenges and Successes. Vaccines. 2020;8(4). doi:10.3390/vaccines8040739
3. Kim KD, Hwang I, Ku KB, Lee S, Kim SJ, Kim C. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses. J Microbiol Biotechnol. 2020;30(8):1109-1115. doi:10.4014/jmb.2006.06006
4. Ng WH, Liu X, Mahalingam S. Development of vaccines for SARS-CoV-2 [ version 1 ; peer review : 1 approved ]. F1000 Res. 2020;9:1-15.
5. WHO. COVID-19 vaccine tracker and landscape. Published 2021. Accessed October 20, 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
6. European Medicines Agency. EMA recommends first COVID-19 vaccine for authorisation in the EU. Published 2020. Accessed October 21, 2021. https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu
7. U.S. Food and Drug Administration. FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine. Published 2020. Accessed October 21, 2021. https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19
8. Italian Ministry of Health. Covid-19 vaccine plan. Published 2021. Accessed October 14, 2021. https://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?lingua=italiano&id=5452&area=nuovoCoronavirus&menu=vuoto
9. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594-599. doi:10.1038/s41586-020-2814-7
10. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/nejmoa2034577
11. Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021;385(12):1078-1090. doi:10.1056/nejmoa2110475
12. Il Sole 24 Ore. Vaccini in tempo reale. Published 2021. Accessed October 21, 2021. https://lab24.ilsole24ore.com/numeri-vaccini-italia-mondo/
13. Italian Medicines Agency. Rapporto sulla Sorveglianza dei vaccini. Published online 2021. https://www.aifa.gov.it/farmacovigilanza-vaccini-covid-19
14. Cugno M, Consonni D, Lombardi A, et al. Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccine in health care workers taking ACE inhibitors. Vaccines. 2021;9(9):1-7. doi:10.3390/vaccines9091011
15. Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. Am J Epidemiol. 2004;159(7):702-706. doi:10.1093/aje/kwh090
16. Kadali RAK, Janagama R, Peruru S, Malayala S V. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376-381. doi:10.1016/j.ijid.2021.04.047
17. Gee J, Paige Marquez ;, Su J, et al. MMWR, First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021.; 2020. https://www.meddra.
18. Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939-949. doi:10.1016/S1473-3099(21)00224-3
19. Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Da Silva FT. The how’s and what’s of vaccine reactogenicity. npj Vaccines. 2019;4(1). doi:10.1038/s41541-019-0132-6
20. Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mrna-based covid-19 vaccines. JAMA - J Am Med Assoc. 2021;325(21):2201-2202. doi:10.1001/jama.2021.5374
21. Ripabelli G, Tamburro M, Buccieri N, et al. Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study. J Community Health. 2021;(0123456789). doi:10.1007/s10900-021-01039-3
22. d’Arminio Monforte A, Tavelli A, Perrone PM, et al. Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers. EClinicalMedicine. 2021;36. doi:10.1016/j.eclinm.2021.100914
23. El Yousfi M, Mercier S, Breuillé D, et al. The inflammatory response to vaccination is altered in the elderly. Mech Ageing Dev. 2005;126(8):874-881. doi:10.1016/j.mad.2005.03.008
24. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10(5):338-349. doi:10.1016/S1473-3099(10)70049-9
25. Trigunaite A, Dimo J, Jørgensen TN. Suppressive effects of androgens on the immune system. Cell Immunol. 2015;294(2):87-94. doi:10.1016/j.cellimm.2015.02.004
26. Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol. 2015;294(2):63-69. doi:10.1016/j.cellimm.2015.01.018
27. Singer K, Lumeng CN. The initiation of metabolic inflammation in childhood obesity. J Clin Invest. 2017;127(1):65-73. doi:10.1172/JCI88882
28. Raw RK, Kelly CA, Rees J, Wroe C, Chadwick DR. Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination. J Infect. 2021;83(3):381-412. doi:10.1016/j.jinf.2021.05.035
29. Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397(10279):1057-1058. doi:10.1016/S0140-6736(21)00501-8
30. Wise J. Covid-19: People who have had infection might only need one dose of mRNA vaccine. BMJ. 2021;372:n308. doi:10.1136/bmj.n308